Currently available therapy for diabetes and diabetic dyslipoproteinemia include insulin and various oral antidiabetic agents such as sulfonylurea, metformin, α-glucosidase inhibitors, troglitazone [6] and anti dyslipoproteinemic agents as gemfibrozil and flavastatin [7], but these are known to have number of serious adverse effects in patients [8, 9].